Evidence map›Paper›PMID 36414349›Full record

ArticleBMJ case reports2022

Kikuchi-Fujimoto disease following SARS-CoV-2 vaccination.

Kohsuke Ikeda, Eiichi Kakehi, Seiji Adachi, Kazuhiko Kotani

Open access · hybridAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Kikuchi-Fujimoto disease: A comprehensive review.World journal of clinical cases · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kohsuke IkedaDepartment of General Medicine, Tottori Municipal Hospital, Tottori, Japan.
Eiichi KakehiDepartment of General Medicine, Tottori Municipal Hospital, Tottori, Japan openwater_swimming5933@yahoo.co.jp.ORCID http://orcid.org/0000-0002-4556-8412
Seiji AdachiDepartment of General Medicine, Tottori Municipal Hospital, Tottori, Japan.
Kazuhiko KotaniDivision of Community and Family Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Jichi Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A previously healthy Japanese woman in her 20s was admitted to our hospital with a 2-week history of fever (39.0°C) and a 1-week history of painful cervical lymphadenopathy. The day before fever onset, she had received her first Pfizer-BioNTech SARS-CoV-2 vaccine in her left arm. She had previously been treated with empirical antibiotics with no improvement. Physical examination revealed painful lymphadenopathy in both posterior cervical regions. CT showed symmetrical lymphadenopathies in the neck, supraclavicular, axillary and inguinal regions as well as hepatosplenomegaly. We suspected lymphoma and performed a lymph node biopsy in the right inguinal region, which revealed necrotising histiocytic lymphadenitis. The patient was, therefore, diagnosed with Kikuchi-Fujimoto disease (KFD). She improved after the corticosteroid therapy. This report highlights the importance of including KFD as a differential diagnosis of lymphadenopathy after SARS-CoV-2 vaccination. Additionally, lymph node biopsy is helpful for diagnosing KFD because it rules out other entities.

Indexed as

COVID-19Histiocytic Necrotizing LymphadenitisLymphadenopathyCOVID-19 VaccinesFemaleFeverHumansPainSARS-CoV-2VaccinationCOVID-19 VaccinesCOVID-19Medical educationVaccination/immunisation

Identifiers

PMID36414349
PMCPMC9685266
OpenAlexW4309592881

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.